Clinicopathology Figures and Survival of Non-Hodgkin’s Lymphoma in Iran

Authors Information
Article Notes and Dates
To Cite : Najafi S, Payandeh M, Sadeghi M. Clinicopathology Figures and Survival of Non-Hodgkin’s Lymphoma in Iran, Int J Cancer Manag. 2017 ;10(1):e5226. doi: 10.17795/ijcp-5226.
Copyright: Copyright © 2017, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. .
Abstract
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Memar B, Aledavood A, Shahidsales S, Ahadi M, Farzadnia M, Raziee HR, et al. The Prognostic Role of Tumor Marker CA-125 in B-Cell non-Hodgkin's Lymphoma. Iran J Cancer Prev. 2015; 8(1): 42-6[PubMed]
  • 2. Aminian O, Abedi A, Chavoshi F, Ghasemi M, Rahmati-Najarkolaei F. Evaluation of Occupational Risk Factors in Non-Hodgkin Lymphoma and Hodgkin's Disease in Iranian Men. Iran J Cancer Prev. 2012; 5(4): 189-93[PubMed]
  • 3. Alexander DD, Mink PJ, Adami HO, Chang ET, Cole P, Mandel JS, et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer. 2007; 120 Suppl 12: 1-39[DOI][PubMed]
  • 4. Muller AM, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol. 2005; 84(1): 1-12[DOI][PubMed]
  • 5. Ansell SM, Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2005; 80(8): 1087-97[DOI][PubMed]
  • 6. Hashemi-Bahremani M, Parwaresch MR, Tabrizchi H, Gupta RK, Raffii MR. Lymphomas in Iran. Arch Iran Med. 2007; 10(3): 343-8[PubMed]
  • 7. Broyde A, Boycov O, Strenov Y, Okon E, Shpilberg O, Bairey O. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma. Am J Hematol. 2009; 84(6): 338-43[DOI][PubMed]
  • 8. Hosseini S, Dehghan P. Primary non-hodgkin lymphoma of the stomach: clinicopathological characteristics and prognostic factors in Iranian patients. Iran J Cancer Prev. 2014; 7(4): 219-24[PubMed]
  • 9. Kahl B. Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma. Semin Hematol. 2008; 45(2): 90-4[DOI][PubMed]
  • 10. Newton R, Ferlay J, Beral V, Devesa SS. The epidemiology of non-Hodgkin's lymphoma: comparison of nodal and extra-nodal sites. Int J Cancer. 1997; 72(6): 923-30[PubMed]
  • 11. Irshaid F, Tarawneh K, Alshdefat A, Dilmi F, Jaran A, Al-Hadithi R, et al. Loss of P16 Protein Expression and Its Association with Epstein-Barr Virus LMP-1 Expression in Hodgkin's Lymphoma. Iran J Cancer Prev. 2013; 6(2): 78-84[PubMed]
  • 12. Aledavood SA, Ghavam-Nasiri MR, Ghaffarzadegan K, Raziee HR, Saboori G, Anvari K, et al. Hepatitis-C Infection Incidence Among the non-Hodgkin's B-cell Lymphoma Patients in the Northeast of Iran. Iran J Cancer Prev. 2014; 7(3): 147-51[PubMed]
  • 13. Barbieri E, Cammelli S, Mauro F, Perini F, Cazzola A, Neri S, et al. Primary non-Hodgkin's lymphoma of the bone: treatment and analysis of prognostic factors for Stage I and Stage II. Int J Radiat Oncol Biol Phys. 2004; 59(3): 760-4[DOI][PubMed]
  • 14. Economopoulos T, Asprou N, Stathakis N, Fountzilas G, Pavlidis N, Papaspyrou S, et al. Primary extranodal non-Hodgkin's lymphoma of the head and neck. Oncology. 1992; 49(6): 484-8[PubMed]
  • 15. Naz E, Mirza T, Aziz S, Danish F, Siddiqui ST, Ali A. Frequency and clinicopathologic correlation of different types of non Hodgkin's lymphoma according to WHO classification. J Pak Med Assoc. 2011; 61(3): 260-3[PubMed]
  • 16. Padhi S, Paul TR, Challa S, Prayaga AK, Rajappa S, Raghunadharao D, et al. Primary extra nodal non Hodgkin lymphoma: a 5 year retrospective analysis. Asian Pac J Cancer Prev. 2012; 13(10): 4889-95[PubMed]
  • 17. Otter R, Gerrits WB, vd Sandt MM, Hermans J, Willemze R. Primary extranodal and nodal non-Hodgkin's lymphoma. A survey of a population-based registry. Eur J Cancer Clin Oncol. 1989; 25(8): 1203-10[PubMed]
  • 18. Payandeh M, Sadeghi M, Sadeghi E. The ki-67 index in non-hodgkin's lymphoma: Role and prognostic significance. American J Cancer Prevention. 2015; 3(5): 100-2
  • 19. Zou GR, Zhang YJ, Xie FY, Zheng W, Li HX, Xia YF, et al. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage]. Ai Zheng. 2006; 25(12): 1543-9[PubMed]
  • 20. Friedberg JW, Fisher RI. Diffuse large B-cell lymphoma. Hematol Oncol Clin North Am. 2008; 22(5): 941-52[DOI][PubMed]
  • 21. Hauptrock B, Hess G. Rituximab in the treatment of non-Hodgkin's lymphoma. Biologics. 2008; 2(4): 619-33[PubMed]
  • 22. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(4): 235-42[DOI][PubMed]
  • 23. Sengar M, Akhade A, Nair R, Menon H, Shet T, Gujral S, et al. A retrospective audit of clinicopathological attributes and treatment outcomes of adolescent and young adult non-Hodgkin lymphomas from a tertiary care center. Indian J Med Paediatr Oncol. 2011; 32(4): 197-203[DOI][PubMed]
  • 24. Payandeh M, Sadeghi M, Shahriari-Ahmadi A, Sadeghi E. The survival of nodal non-hodgkin's lymphoma patients in the west of Iran. American J Cancer Prevention. 2015; 3(5): 103-5
  • 25. Payandeh M, Sadeghi M, Sadeghi E, Aeinfar M. The survival of extra nodal non-hodgkin's lymphoma patients in the west of Iran. American J Cancer Prevention. 2015; 3(5): 96-9
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By: